Achillion: Clinical Trial Update (Achillion) - Jul 25, 2015 - “ACH-3422 achieved dose-related virologic responses in GT-1 HCV-infected patients. In the 6 patients who received 700 mg QD for 14 days, mean maximal reduction from baseline was 4.6 log10, including 3 patients with target not detected”; “In all HVs and patients infected with HCV who received active treatment through 700mg QD, AC-3422 was safe and well-tolerated with no treatment-related SAEs, AE-related discontinuations, or clinically significant laboratory or ECG abnormalities”
P1 data • Hepatitis C Virus
|